TABLE 3.
Ongoing therapies in combination with mTOR inhibitors and their highest clinical trial phase in various tumor types based on the GlobalData database.
| Tumor types | Therapy | Highest phase and ID number of the clinical trial |
|---|---|---|
| Breast Tumors | ||
| Marketed: Metastatic, hormone receptor+/HER2− Breast Cancer (everolimus) | ||
| HER2+ (hormone receptor−/HER2+) Breast Cancer | chemotherapy + inetetamab + sirolimus | Phase III—NCT04736589 |
| Luminal A (hormone receptor+/HER2−) Breast Cancer | AZD2014/everolimus + fulvestrant | Phase II—NCT02216786 |
| everolimus + paclitaxel | Phase II—NCT04355858 | |
| Triple-Negative Breast Cancer | AZD2014 + AZD6244 (MEKI) | Phase I/II — NCT02583542 |
| bevacizumab + doxorubicin + everolimus | Phase II—NCT02456857 | |
| AZD6244 + temsirolimus | Phase I—NCT00600496 | |
| Central Nervous System Tumors | ||
| Marketed: Astrocytoma (everolimus) | ||
| perifosine + temsirolimus | Phase I—NCT02238496 | |
| cyclophosphamide + dasatinib + temsirolimus | Phase I—NCT02389309 | |
| temsirolimus + vorinostat | Phase I—NCT02420613 | |
| irinotecan + nab-rapamycin + temozolomide | Phase I—NCT02975882 | |
| everolimus + trametinib | Phase I—NCT04485559 | |
| celecoxib + cyclophosphamide + etoposide + sirolimus | Phase II—NCT02574728 | |
| nab-rapamycin + standard therapy | Phase II—NCT03463265 | |
| Digestive System Tumors | ||
| Colorectal Cancer | AZD6244 + temsirolimus | Phase I—NCT00600496 |
| bevacizumab + FOLFOX6 + nab-rapamycin | Phase I/II—NCT03439462 | |
| Hepatocellular Carcinoma | everolimus + lenvatinib + trametinib | Phase II—NCT04803318 |
| Pancreatic Cancer | gedatolisib + palbociclib | Phase I — NCT03065062 |
| Head and Neck Tumors | ||
| gedatolisib + palbociclib | Phase I—NCT03065062 | |
| Neuroendocrine Tumors | ||
| Marketed: Neuroendocrine Tumors of the Lungs, Pancreas, or Intestines (everolimus) | ||
| Neurofibromatosis | PLX3397 (MTKI) + sirolimus | Phase I/II—NCT02584647 |
| selumetinib (MEKI) + sirolimus | Phase II—NCT03433183 | |
| bevacizumab + everolimus + octreotide acetate | Phase II—NCT01229943 | |
| everolimus + lenvatinib | Phase II—NCT03950609 | |
| Other Tumors | ||
| Advanced Tumor | sirolimus/everolimus/temsirolimus + vorinostat | Phase I—NCT01087554 |
| bevacizumab + carboplatin/sorafenib/paclitaxel + temsirolimus | Phase I—NCT01187199 | |
| everolimus + vandetanib | Phase I—NCT01582191 | |
| ceritinib + everolimus | Phase I—NCT02321501 | |
| cemiplimab + sirolimus/everolimus + prednisone | Phase I—NCT04339062 | |
| Hepatoblastoma | chemotherapy + temsirolimus | Phase III—NCT00980460 |
| Neuroblastoma | irinotecan + temozolomide + temsirolimus | Phase II—NCT01767194 |
| Solid Tumor | ixabepilone + temsirolimus | Phase I—NCT01375829 |
| cyclophosphamide + dasatinib + temsirolimus | Phase I—NCT02389309 | |
| bevacizumab + cyclophosphamide + temsirolimus + valproát | Phase I—NCT02446431 | |
| irinotecan + nab-rapamycin + temozolomide | Phase I—NCT02975882 | |
| gedatolisib + palbociclib | Phase I—NCT03065062 | |
| epacadostat + sirolimus | Phase I—NCT03217669 | |
| celecoxib + cyclophosphamide + etoposide + sirolimus | Phase II—NCT02574728 | |
| everolimus + lenvatinib + trametinib | Phase II—NCT04803318 | |
| Vascular Tumor | prednisolone + sirolimus | Phase II—NCT03188068 |
| Skin Tumors | ||
| Melanoma | AZD6244 + temsirolimus | Phase I—NCT00600496 |
| Soft Tissue and Bone Tumors | ||
| chemotherapy + everolimus + temsirolimus | Phase I—NCT04199026 | |
| nab-rapamycin + pazopanib hydrochloride | Phase I/II—NCT03660930 | |
| everolimus + ribociclib | Phase II—NCT03114527 | |
| chemotherapy + temsirolimus | Phase III—NCT02567435 | |
| Thoracic Tumors | ||
| Marketed: Sporadic Lymphangioleiomyomatosis (sirolimus) | ||
| Non-Small Cell Lung Cancer | gedatolisib + palbociclib | Phase I—NCT03065062 |
| epacadostat + sirolimus | Phase I—NCT03217669 | |
| durvalumab + sirolimus | Phase I—NCT04348292 | |
| AZD2014 + AZD6244 (MEKI) | Phase I/II—NCT02583542 | |
| Non-Small Cell Lung Cancer + Small Cell Lung Cancer | AZD6244 + temsirolimus | Phase I—NCT00600496 |
| auranofin + sirolimus | Phase I/II—NCT01737502 | |
| Tumors of Haematopoietic and Lymphoid Tissues | ||
| Marketed: Mantle Cell Lymphoma (temsirolimus) | ||
| Hodgkin’s Lymphoma | everolimus + itacitinib | Phase I/II—NCT03697408 |
| Leukemia | decitabine + sirolimus | Phase I/II—NCT02109744 |
| azacitidine + sirolimus | Phase II—NCT01869114 | |
| clofarabine + melphalan + sirolimus + tacrolimus | Phase II—NCT01885689 | |
| Urinary and Male Genital Tumors | ||
| Marketed: Metastatic Kidney Cancer (everolimus, temsirolimus) | ||
| Kidney Cancer | AZD6244 + temsirolimus | Phase I—NCT00600496 |
| DFF332 (HIF2αI) + everolimus | Phase I—NCT04895748 | |
| sunitinib + temsirolimus | Phase II—NCT01517243 | |
| everolimus + lenvatinib | Phase I—NCT03324373 | |
| Phase II—NCT05012371 | ||
| anastrozol + AZD2014 | Phase I/II—NCT02730923 | |
| carboplatin + paclitaxel + temsirolimus | Phase II—NCT00977574 | |
| everolimus + levonorgestrel | Phase II—NCT02397083 | |
| everolimus + letrozole + ribociclib | Phase II—NCT03008408 | |
| auranofin + sirolimus | Phase II—NCT03456700 | |
| ATG008/ATG010 | Phase II—NCT04998760 | |